Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.70 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.61 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.61 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.61 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4654433 | 0.92 | NLRP3 (0.78) | NLRP3ABCC9ABCC8KCNJ11DNMT3A | |
| SCHEMBL6364338 | 0.88 | NLRP3 (0.53) | NLRP3ABCC9ABCC8KCNJ11DNMT3A | |
| SCHEMBL7019461 | 0.87 | NLRP3 (0.74) | NLRP3ABCC9ABCC8KCNJ11DNMT3A | |
| SCHEMBL3767959 | 0.86 | NLRP3 (0.73) | NLRP3ABCC9ABCC8KCNJ11DNMT3A | |
| SCHEMBL7023830 | 0.85 | NLRP3 (0.71) | NLRP3ABCC9ABCC8KCNJ11DNMT3A | |
| SCHEMBL726272 | 0.85 | ABCC9 (0.87) | NLRP3ABCC9ABCC8KCNJ11DNMT3A | |
| SCHEMBL7025679 | 0.84 | NLRP3 (0.67) | NLRP3ABCC9ABCC8KCNJ11DNMT3A | |
| SCHEMBL6567784 | 0.84 | ABCC9 (0.85) | NLRP3ABCC9ABCC8KCNJ11DNMT3A | |
| SCHEMBL6567790 | 0.84 | ABCC9 (0.85) | NLRP3ABCC9ABCC8KCNJ11DNMT3A | |
| SCHEMBL7077160 | 0.84 | ABCC9 (0.66) | NLRP3ABCC9ABCC8KCNJ11DNMT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401419-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | disclosed |
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | GERLACH UWE (DE) | 2003-05-01 | — | — | US | disclosed |
| WO-2003000244-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | UTS2R, EIF2S1, TST | NLRP3 1539/4885ABCC9 551/4885ABCC8 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.